Espositori 2019
- 3D PRINTING
- ART
- EDUCATION
- HOME AUTOMATION
- INTERNET OF THINGS
- KIDS & EDUCATION
- RECYCLING & UPCYCLING
- ROBOTICS
- SCIENCE
- YOUNG MAKERS (< 18)
- BIOLOGY
- GAMES
- ARTIFICIAL INTELLIGENCE
- OPEN SOURCE
- NEW MANUFACTURING
- FABRICATION
- WELLNESS & HEALTHCARE
- ENERGY & SUSTAINABILITY
- FOOD & AGRICULTURE
- 3D SCANNING
- CULTURAL HERITAGE
- AEROSPACE
- HACKS
- MUSIC & SOUND
- ARTISANS & NEW CRAFT
- FASHION & WEARABLES
- DRONES
- STEAM PUNK
- ARDUINO
- CROWDFUNDING
Nuovi farmaci ed un'energia innovativa grazie alla luce del sole e ad una proteina
The first application delivered by the technology platform will be a combined optopharmacology and optogenetics approach to improve and restore visual functions in retinal diseases. Indeed, rhodopsin is a membrane receptor belonging to the superfamily of G-protein coupled receptor (GPCR) that is responsible for photoreception in the vertebrate retina. Aberrant expression of rhodopsin is linked to Retinitis Pigmentosa (RP), a group of retinal diseases that provokes defects in the visual function up to blindness. These may include optopharmacology tools, namely small molecules able to restore rhodopsin function and signaling acting through multiple mechanisms, as well as optogenetics strategies to target wild-type and modified opsin genes to surviving retinal cells through suitable delivery models.
To accomplish such goals new human resources will be enrolled and trained for the project and new facilities will be set-up at DBCF: the High Performance Computing Centre, the Mass Spectroscopy centre and the High Throughput Screening lab.